InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by ALCORN HARRY W JR, SVP, Opérations Cliniques. Officer active across 1 companies, notably DiaMedica Therapeutics Inc.. Aggregated, 4 filings have been recorded. Total volume traded: €201k. The latest transaction was filed on 15 September 2021 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations4 total
€48,18915,000 shares@ €3.212647.9% of flow
Voting Common Shares, no par value per share
SEC:0001235802-21-000119·
Ideal exit: 12 Jun 2022 (T+270)
€48,18915,000 shares@ €3.21260.012% mcap23.9% of flow
Voting Common Shares, no par value per share
SEC:0001235802-21-000119:0·
Ideal exit: 12 Jun 2022 (T+270)
€52,49920,000 shares@ €2.62552.1% of flow
Voting Common Shares, no par value per share
SEC:0001235802-21-000099·
Ideal exit: 13 May 2022 (T+270)
€52,49920,000 shares@ €2.6250.013% mcap26.1% of flow
Voting Common Shares, no par value per share
SEC:0001235802-21-000099:0·
Ideal exit: 13 May 2022 (T+270)
4 of 4 declarations
About ALCORN HARRY W JR
Harry W. Alcorn Jr. is the Senior Vice President of Clinical Operations at DiaMedica Therapeutics Inc. In this role, he oversees the company's clinical operations, ensuring that clinical trials are conducted efficiently. With experience in the biopharmaceutical sector, he plays a key role in developing new treatments.
